A Plus Biotechnology Co (TPE:6918) Beginning Cash Position: NT$604.4 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:6918 A Plus Biotechnology Co Ltd TPE:6918
69 GF Score
Price NT$70.40
GF Value NT$86.71
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is A Plus Biotechnology Co Beginning Cash Position?

A Plus Biotechnology Co TPE:6918 69 Beginning Cash Position is NT$604.4 Mil as of Mar. 2026. GuruFocus rates TPE:6918 with a GF Score™ of 69/100 and a GF Value™ of NT$86.71 (Modestly Undervalued). The stock has 3 warning signs investors should review.

A Plus Biotechnology Co's Beginning Cash Position for the quarter that ended in Mar. 2026 was NT$604.4 Mil.

A Plus Biotechnology Co's quarterly Beginning Cash Position declined from Sep. 2025 (NT$665.9 Mil) to Dec. 2025 (NT$488.9 Mil) but then increased from Dec. 2025 (NT$488.9 Mil) to Mar. 2026 (NT$604.4 Mil).

A Plus Biotechnology Co's annual Beginning Cash Position increased from Dec. 2023 (NT$237.7 Mil) to Dec. 2024 (NT$319.1 Mil) and increased from Dec. 2024 (NT$319.1 Mil) to Dec. 2025 (NT$361.0 Mil).

A Plus Biotechnology Co Beginning Cash Position Related Terms

A Plus Biotechnology Co Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for A Plus Biotechnology Co's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A Plus Biotechnology Co Beginning Cash Position Chart

A Plus Biotechnology Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial 289.31 305.09 237.69 319.07 360.97

A Plus Biotechnology Co Quarterly Data
Dec19 Dec20 Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 360.97 407.31 665.88 488.92 604.35
TPE:6918
69GF Score
A Plus Biotechnology Co Ltd TPE:6918
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

A Plus Biotechnology Co Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of NT$604.4 Mil mean?
A Plus Biotechnology Co (TPE:6918) has a Beginning Cash Position of NT$604.4 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on A Plus Biotechnology Co and its competitors.
Is A Plus Biotechnology Co's Beginning Cash Position too high?
A Plus Biotechnology Co's current Beginning Cash Position is NT$604.4 Mil. Overall, A Plus Biotechnology Co has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does A Plus Biotechnology Co's Beginning Cash Position compare to ABT and SYK?
A Plus Biotechnology Co's Beginning Cash Position of NT$604.4 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Medical Devices & Instruments company?
A good Beginning Cash Position depends on the Medical Devices & Instruments industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on A Plus Biotechnology Co and its competitors. A Plus Biotechnology Co's current Beginning Cash Position is NT$604.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is A Plus Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, A Plus Biotechnology Co (TPE:6918) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$86.71, compared to a current price of NT$70.40 — trading 18.8% below its estimated fair value. The current Beginning Cash Position is NT$604.4 Mil. A Plus Biotechnology Co's overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For A Plus Biotechnology Co (TPE:6918), the current Beginning Cash Position is NT$604.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is A Plus Biotechnology Co (TPE:6918) Overvalued in 2026?

Based on GuruFocus' analysis, A Plus Biotechnology Co stock appears to be undervalued. The current stock price of NT$70.40 is trading 18.8% below its estimated GF Value™ of NT$86.71. GuruFocus considers A Plus Biotechnology Co to be Modestly Undervalued.

Key valuation signals for TPE:6918:

  • Beginning Cash Position: NT$604.4 Mil
  • GF Value™: NT$86.71 vs. price of NT$70.40 (18.8% below fair value)
  • GF Score™: 69/100 with 3 warning signs

No single metric tells the full story. See the TPE:6918 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

A Plus Biotechnology Co Business Description

Address No. 21, Qiaohe Road, 3rd Floor, Zhonghe District, New Taipei City, TWN
A Plus Biotechnology Co Ltd provides orthopedic implants and engages in the manufacturing and wholesale of medical devices such as bone material. The company's products include Chest, Shoulder, Spine, Elbow, Wrist & Hand, Pelvic & Hip, Knee, Foot & Ankle, Osteotomy, Pediatric & ESF, and Biologics. The company currently has operating segments in Taiwan and China, with the majority of revenue coming from Taiwan.
69GF Score

Get the complete analysis for TPE:6918

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$70.40
Price
NT$86.71
GF Value